Published in Neuropharmacology on April 15, 2013
Regulation of cellular communication by signaling microdomains in the blood vessel wall. Pharmacol Rev (2014) 0.90
Aberrant connexin26 hemichannels underlying keratitis-ichthyosis-deafness syndrome are potently inhibited by mefloquine. J Invest Dermatol (2014) 0.84
A rapid and sensitive assay of intercellular coupling by voltage imaging of gap junction networks. Cell Commun Signal (2013) 0.82
Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury. Oncotarget (2015) 0.80
Connexin hemichannels influence genetically determined inflammatory and hyperproliferative skin diseases. Pharmacol Res (2015) 0.79
The Role of the Mucosa in Normal and Abnormal Bladder Function. Basic Clin Pharmacol Toxicol (2016) 0.79
Innexin AGAP001476 is critical for mediating anti-Plasmodium responses in Anopheles mosquitoes. J Biol Chem (2014) 0.78
Functional hemichannels formed by human connexin 26 expressed in bacteria. Biosci Rep (2015) 0.76
Purinergic Signaling in Gut Inflammation: The Role of Connexins and Pannexins. Front Neurosci (2016) 0.75
Recurrent seizure-like events are associated with coupled astroglial synchronization. Front Cell Neurosci (2015) 0.75
On Biophysical Properties and Sensitivity to Gap Junction Blockers of Connexin 39 Hemichannels Expressed in HeLa Cells. Front Physiol (2017) 0.75
Synchrony and so much more: Diverse roles for electrical synapses in neural circuits. Dev Neurobiol (2017) 0.75
The double life of connexin channels: single is a treat. J Invest Dermatol (2015) 0.75
Simvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 Protein. PLoS One (2016) 0.75
A Cell-Based Assay to Assess Hemichannel Function. Yale J Biol Med (2017) 0.75
Descending Vasa Recta Endothelial Membrane Potential Response Requires Pericyte Communication. PLoS One (2016) 0.75
Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications. Pharmacol Rev (2017) 0.75
Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J Gen Physiol (1971) 14.23
The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev (2003) 9.76
Emerging issues of connexin channels: biophysics fills the gap. Q Rev Biophys (2001) 4.76
Structure of the connexin 26 gap junction channel at 3.5 A resolution. Nature (2009) 4.44
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A (2000) 4.01
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. J Neurochem (2005) 3.87
Opposite voltage gating polarities of two closely related connexins. Nature (1994) 3.72
Voltage gating and permeation in a gap junction hemichannel. Proc Natl Acad Sci U S A (1996) 3.65
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2+ signaling. J Neurosci (2006) 3.14
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem (1988) 3.04
Properties of a nonjunctional current expressed from a rat connexin46 cDNA in Xenopus oocytes. J Gen Physiol (1993) 2.64
Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci U S A (2004) 2.61
Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res (2008) 2.43
Gap junction channel gating. Biochim Biophys Acta (2004) 2.34
Glycyrrhetinic acid derivatives: a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships. J Pharmacol Exp Ther (1988) 2.31
Structure-activity relations of the cardiac gap junction channel. Am J Physiol (1990) 2.00
Interaction of anaesthetics with electrical synapses. Nature (1980) 1.97
Reversible inhibition of intercellular junctional communication by glycyrrhetinic acid. Biochem Biophys Res Commun (1986) 1.95
Volatile anesthetics block intercellular communication between neonatal rat myocardial cells. Circ Res (1989) 1.90
Connexin mimetic peptides reversibly inhibit Ca(2+) signaling through gap junctions in airway cells. Am J Physiol Lung Cell Mol Physiol (2000) 1.83
Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.72
Lens gap junctions in growth, differentiation, and homeostasis. Physiol Rev (2010) 1.70
Carbenoxolone inhibition of voltage-gated Ca channels and synaptic transmission in the retina. J Neurophysiol (2004) 1.70
Hemichannel and junctional properties of connexin 50. Biophys J (2002) 1.69
Quinine blocks specific gap junction channel subtypes. Proc Natl Acad Sci U S A (2001) 1.67
Electrical coupling and excitatory synaptic transmission between rhythmogenic respiratory neurons in the preBötzinger complex. J Neurosci (2000) 1.65
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol (2005) 1.63
Correlative studies of gating in Cx46 and Cx50 hemichannels and gap junction channels. Biophys J (2004) 1.62
Two distinct gating mechanisms in gap junction channels: CO2-sensitive and voltage-sensitive. Biophys J (1997) 1.61
Carbenoxolone blockade of neuronal network activity in culture is not mediated by an action on gap junctions. J Physiol (2003) 1.59
GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum Mutat (2009) 1.52
Peptides homologous to extracellular loop motifs of connexin 43 reversibly abolish rhythmic contractile activity in rabbit arteries. J Physiol (1997) 1.51
Inhibition of gap junction hemichannels by chloride channel blockers. J Membr Biol (2002) 1.50
Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci U S A (1999) 1.49
Fenamates: a novel class of reversible gap junction blockers. J Pharmacol Exp Ther (2001) 1.49
Differentially altered Ca2+ regulation and Ca2+ permeability in Cx26 hemichannels formed by the A40V and G45E mutations that cause keratitis ichthyosis deafness syndrome. J Gen Physiol (2010) 1.45
Arrhythmogenic cardiomyopathy and abnormalities of cell-to-cell coupling. Heart Rhythm (2009) 1.41
Selective optimization of side activities: another way for drug discovery. J Med Chem (2004) 1.37
Loop gating of connexin hemichannels involves movement of pore-lining residues in the first extracellular loop domain. J Biol Chem (2008) 1.36
Direct actions of carbenoxolone on synaptic transmission and neuronal membrane properties. J Neurophysiol (2009) 1.34
Effect of external magnesium and calcium on human connexin46 hemichannels. Biophys J (2003) 1.33
Gap junction remodeling and cardiac arrhythmogenesis in a murine model of oculodentodigital dysplasia. Proc Natl Acad Sci U S A (2007) 1.33
Role of heterocellular Gap junctional communication in endothelium-dependent smooth muscle hyperpolarization: inhibition by a connexin-mimetic peptide. Biochem Biophys Res Commun (1999) 1.27
Divalent cations regulate connexin hemichannels by modulating intrinsic voltage-dependent gating. J Gen Physiol (2008) 1.26
Prospects for rational development of pharmacological gap junction channel blockers. Curr Drug Targets (2002) 1.22
Closure of gap junction channels by arylaminobenzoates. Mol Pharmacol (2003) 1.21
Pharmacological sensitivity of ATP release triggered by photoliberation of inositol-1,4,5-trisphosphate and zero extracellular calcium in brain endothelial cells. J Cell Physiol (2003) 1.21
The role of gap junctions in seizures. Brain Res Brain Res Rev (2000) 1.20
Block of specific gap junction channel subtypes by 2-aminoethoxydiphenyl borate (2-APB). J Pharmacol Exp Ther (2006) 1.20
Charges dispersed over the permeation pathway determine the charge selectivity and conductance of a Cx32 chimeric hemichannel. J Physiol (2008) 1.20
Photoliberating inositol-1,4,5-trisphosphate triggers ATP release that is blocked by the connexin mimetic peptide gap 26. Cell Calcium (2003) 1.20
Molecular dynamics simulations of the Cx26 hemichannel: evaluation of structural models with Brownian dynamics. J Gen Physiol (2011) 1.19
Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc Natl Acad Sci U S A (1998) 1.18
Conformational changes in a pore-forming region underlie voltage-dependent "loop gating" of an unapposed connexin hemichannel. J Gen Physiol (2009) 1.18
Voltage-dependent blockade of connexin40 gap junctions by spermine. Biophys J (2003) 1.18
Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol (2012) 1.17
Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol (2004) 1.15
Long-chain n-alkanols and arachidonic acid interfere with the Vm-sensitive gating mechanism of gap junction channels. Pflugers Arch (1998) 1.14
Connexin-26 mutations in deafness and skin disease. Expert Rev Mol Med (2009) 1.12
Pharmacological and genetic approaches to study connexin-mediated channels in glial cells of the central nervous system. Brain Res Rev (2009) 1.12
The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br J Pharmacol (2000) 1.11
2-aminoethoxydiphenyl borate directly inhibits channels composed of connexin26 and/or connexin32. Mol Pharmacol (2006) 1.10
Severe neuropathy with leaky connexin32 hemichannels. Ann Neurol (2005) 1.07
Gap junctions in inherited human disorders of the central nervous system. Biochim Biophys Acta (2011) 1.05
The Cx26-G45E mutation displays increased hemichannel activity in a mouse model of the lethal form of keratitis-ichthyosis-deafness syndrome. Mol Biol Cell (2011) 1.04
Cell-cell communication in heterocellular cultures of alveolar epithelial cells. Am J Respir Cell Mol Biol (2003) 1.03
Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther (2001) 1.03
Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochim Biophys Acta (2005) 1.03
Effect of several uncouplers of cell-to-cell communication on gap junction morphology in mammalian heart. J Membr Biol (1983) 1.02
Gap26, a connexin mimetic peptide, inhibits currents carried by connexin43 hemichannels and gap junction channels. Pharmacol Res (2012) 1.00
Effects of connexin-mimetic peptides on gap junction functionality and connexin expression in cultured vascular cells. Br J Pharmacol (2005) 1.00
Pore-lining residues identified by single channel SCAM studies in Cx46 hemichannels. Cell Commun Adhes (2003) 0.98
Connexin mimetic peptides inhibit Cx43 hemichannel opening triggered by voltage and intracellular Ca2+ elevation. Basic Res Cardiol (2012) 0.97
Permeation pathway of homomeric connexin 26 and connexin 30 channels investigated by molecular dynamics. J Biomol Struct Dyn (2012) 0.96
Reversible pore block of connexin channels by cyclodextrins. J Biol Chem (2004) 0.95
Identification of gap junction blockers using automated fluorescence microscopy imaging. J Biomol Screen (2003) 0.94
The N-terminal half of the connexin protein contains the core elements of the pore and voltage gates. J Membr Biol (2012) 0.93
Analysis of effects of connexin-mimetic peptides in rat mesenteric small arteries. Am J Physiol Heart Circ Physiol (2006) 0.93
Inhibition of volume-regulated and calcium-activated chloride channels by the antimalarial mefloquine. J Pharmacol Exp Ther (2000) 0.92
Glial hemichannels and their involvement in aging and neurodegenerative diseases. Rev Neurosci (2012) 0.91
Ionic blockade of the rat connexin40 gap junction channel by large tetraalkylammonium ions. Biophys J (2001) 0.90
Connexin modulators and their potential targets under the magnifying glass. Curr Med Chem (2010) 0.90
Gap junction-mimetic peptides do work, but in unexpected ways. Cell Commun Adhes (2008) 0.90
Is connexin36 critical for GABAergic hypersynchronization in the hippocampus? J Physiol (2011) 0.90
Tales of a dirty drug: carbenoxolone, gap junctions, and seizures. Epilepsy Curr (2012) 0.90
How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease? Brain Res (2012) 0.87
Role of gap junctions in epilepsy. Neurosci Bull (2011) 0.87
Mechanism of inhibition of connexin channels by the quinine derivative N-benzylquininium. J Gen Physiol (2012) 0.85
Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther (2010) 0.85
Mechanism for modulation of gating of connexin26-containing channels by taurine. J Gen Physiol (2011) 0.85
The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy. Biomed Pharmacother (2005) 0.83
A high-throughput assay for connexin 43 (Cx43, GJA1) gap junctions using codon-optimized aequorin. Assay Drug Dev Technol (2012) 0.83
Human connexin channel specificity of classical and new gap junction inhibitors. J Biomol Screen (2012) 0.82
Triarylmethanes, a new class of cx50 inhibitors. Front Pharmacol (2012) 0.76
Gap junction hemichannel interactions with zwitterionic lipid, anionic lipid, and cholesterol: molecular simulation studies. Biochemistry (2011) 0.76
Human diseases associated with connexin mutations. Biochim Biophys Acta (2017) 0.75